The publication of modern slavery statements (statements) on this Register does not indicate compliance with the requirements of the Modern Slavery Act 2018 (the Act). Pursuant to section 19(2) of the Act, the Attorney-General’s Department publishes all statements properly submitted to this Register, including compliant and non-compliant statements, in order to maximise transparency and ensure entities are publicly accountable for their actions to address modern slavery risks. Statements that fail to meet the requirements for approval and signature set out in sections 13(2) or 14(2) of the Act will not be registered.

Number
2022-1698
Type
Single
Period
01 July 2021 to 30 June 2022
Annual revenue
100-150M
Industry sectors
Healthcare and pharmaceuticals
Countries
Japan
Key brands and business names
Xtandi, Betmiga, Xospata, Mycamine, Prograf, Advagraf XL, Flomaxtra, Vesicare
Date submitted
29/09/2022
Date published
21/12/2022